# Dexcom (DXCM) Q2 2026 earnings

Results filed 2026-07-30 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/dxcm/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/0001093557-26-000142-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Dexcom's CONNECT trial showed CGM benefits for type 2 diabetes patients not on insulin, while a Stelo app relaunch and Nutrisense acquisition push it toward broader, consumer-facing glucose sensing.

Dexcom's main product news this quarter was clinical and consumer. The CONNECT randomized controlled trial found that CGM use in people with type 2 diabetes not using insulin improved glucose control compared with routine care. Dexcom also began launching a reimagined Stelo app with AI-driven insights and better food logging, and completed the acquisition of Nutrisense. International revenue grew 19% reported, outpacing the U.S.
Management is steering toward a much larger user base, citing about 9 million people in the U.S. who have CGM coverage but don't use it, and a long-term outlook through 2030 presented at Investor Day. The plan depends on converting nearly 50% of the U.S. base to G7 15 Day by year end, extending coverage, and a CMS decision expected this year. The tension is that growth rests on payer and regulatory decisions outside Dexcom's control.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $1.308 billion | up 13% from a year ago on a reported basis | GAAP |
| Net income | $249.1 million | up from $179.8 million a year ago | GAAP |
| Diluted EPS | $0.64 | up from $0.45 a year ago | GAAP |
| Non-GAAP diluted EPS | $0.70 | up from $0.48 a year ago | non-GAAP |
| Gross margin | 63.4% | up from 59.5% a year ago | GAAP |
| Operating income | $318.3 million | up from $212.6 million a year ago | GAAP |
| Operating margin | 24.3% | up 590 basis points from a year ago | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| U.S. revenue | $933.4 | up 11% from a year ago |
| International revenue | $375.0 | up 19% reported, 16% organic |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue | fiscal year 2026 | $5.18 - $5.25 billion |
| Non-GAAP gross profit margin | fiscal year 2026 | approximately 64% |
| Non-GAAP operating margin | fiscal year 2026 | approximately 23.5-24% |
| Adjusted EBITDA margin | fiscal year 2026 | approximately 31.5-32% |

## Key takeaways

1. **CONNECT trial supports CGM for non-insulin type 2** Dexcom reported that CGM use among people with type 2 diabetes not using insulin produced clinically meaningful, statistically significant improvements in glucose control versus routine care. This evidence underpins the push into a much larger patient group.
2. **Stelo app relaunched with AI insights** Dexcom started rolling out a reimagined Stelo experience with a more consumer-friendly feel, AI-driven insights and enhanced food logging. It signals deeper investment in the over-the-counter consumer segment.
3. **Nutrisense acquisition completed in the quarter** Dexcom completed its acquisition of Nutrisense during the second quarter, adding to its consumer and wellness-oriented glucose offerings. Acquired non-CGM revenue was only $0.2 million, so it is early.
4. **G7 15 Day conversion and international clearance** Dexcom is on track to convert nearly 50% of its U.S. customer base to G7 15 Day by year end, and Health Canada was the first international regulator to clear it. The product also contributes to expected gross margin gains.
5. **Payer coverage broadens, CMS decision pending** Dexcom now has coverage for all people with diabetes across the 4 largest commercial PBMs, and expects to hear back from CMS before the end of this year. Coverage decisions are the main gate to the roughly 9 million covered but non-using people in the U.S.

## Questions

**What did Dexcom's CONNECT trial show?** It showed that CGM use among people with type 2 diabetes not using insulin led to clinically meaningful and statistically significant improvements in glucose control compared with routine care. Dexcom says it reinforces confidence in its long-range plan.
**What is new with Dexcom's Stelo?** Dexcom began launching a fully reimagined Stelo app with a more consumer-friendly feel, new AI-driven insights and enhanced food logging. It also completed the Nutrisense acquisition during the quarter.
**How far along is the G7 15 Day rollout?** Dexcom is on track to convert nearly 50% of its U.S. customer base to G7 15 Day by year end. Health Canada became the first international regulator to clear it.
**How large is the untapped U.S. opportunity Dexcom cites?** Approximately 9 million people in the U.S. have coverage for CGM but are not yet using it. Coverage now spans all people with diabetes across the 4 largest commercial PBMs.
**What did Dexcom lay out at Investor Day?** Dexcom hosted its 2026 Investor Day at its Arizona manufacturing facility, highlighting its market opportunity, strategy and innovation efforts. It introduced a new long-term financial outlook through 2030.

## Slides and investor documents

- [Presentation](https://s201.q4cdn.com/758408164/files/doc_financials/2026/q2/Q226-Investor-Web-Deck_FINAL.pdf) (Slide deck)
- [Webcast](https://events.q4inc.com/attendee/837710277) (Webcast replay)
- [Form 10-Q](https://d18rn0p25nwr6d.cloudfront.net/CIK-0001093557/5f56a5b0-7add-4897-a836-5f16c6e53c20.pdf) (Document)

